Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling

Michael G. Sugiyama ¹, Aidan I. Brown ², Jesus Vega-Lugo ³, Andrew M. Scott ⁴, Khuloud Jaqaman ³, Gregory D. Fairn ⁵, Costin N. Antonescu ^{1*}

1. Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada
2. Department of Physics, Ryerson University, Toronto, Ontario, Canada
3. Department of Biophysics, and Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
4. Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, Victoria, Australia
5. Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

* to whom correspondence should be addressed: cantonescu@ryerson.ca.

Abstract

The epidermal growth factor receptor (EGFR) is a central regulator of cell physiology. EGFR is activated by ligand binding, triggering receptor dimerization, activation of kinase activity, and intracellular signaling. EGFR is transiently confined within various plasma membrane nanodomains, yet how this may contribute to regulation of EGFR ligand binding is poorly understood. To resolve how EGFR nanoscale compartmentalization gates ligand binding, we developed single-particle tracking methods to track the mobility of ligand-bound and total EGFR, in combination with modeling of EGFR ligand binding. In comparison to unliganded EGFR, ligand-bound EGFR was more confined and distinctly regulated by clathrin and tetraspanin nanodomains. Ligand binding to unliganded EGFR occurred preferentially in tetraspanin nanodomains, and disruption of tetraspanin nanodomains impaired EGFR ligand binding and altered the conformation of the receptor's ectodomain. We thus reveal a novel mechanism by which EGFR confinement within tetraspanin nanodomains regulates receptor signaling at the level of ligand binding.

Introduction

The binding of epidermal growth factor (EGF) to its receptor (EGFR) triggers the activation of a wide range of intracellular signaling that in turn regulates many aspects of cell physiology^{1–3}. EGFR is also a key driver of tumor progression and drug resistance in many cancers. Despite the importance of EGFR in physiology and disease, our understanding of the cellular mechanisms that control the initial stages of EGFR signaling such as ligand binding and receptor activation remain incomplete.

The binding of ligands such as EGF to EGFR in cells has complex kinetics reflecting multilayered regulation of this initial stage of EGFR signal activation. In addition to high (K_d of ~0.1 nM, ~10% of surface-exposed receptor) and low (K_d of 2-6 nM, ~90% of surface exposed receptor) affinity subpopulations^{4–9} the ligand binding affinity of EGFR is regulated by signaling, as very low concentrations of EGF reduce the ligand binding affinity of unliganded receptors¹⁰. Structural studies provide some key insights into the potential regulation of EGFR ligand binding. The EGFR ectodomain is comprised of four domains (I-IV), and EGF binding to domains I and III is coupled to a conformational change that allows formation of back-to-back EGFR dimers via contacts within domain II^{1,11,12}. This conformational rearrangement of the ectodomain is coupled to formation of asymmetric dimers and phosphorylation of the EGFR C-terminal tail on multiple distinct tyrosine residues, each of which contribute to activation of specific signaling pathways¹³.

EGFR extracellular domains II and IV form contacts to form a closed or tethered conformation that disfavours activating dimerization; mutation of these residues increased ligand binding^{14–16}. Molecular dynamics simulation and structural studies predict that the transition of EGFR from this tethered (closed) to the open-ligand bound state happens through an extended, open conformation of the EGFR ectodomain¹⁴. The complex regulation of EGFR ligand binding suggests that this transition from tethered (closed) to open (ligand-bound) conformations is not merely stochastic but controlled by cellular mechanisms, yet molecular underpinnings of this regulation remain poorly understood.

The study of distinct behaviours of individual EGFR molecules that may each exhibit distinct regulation of ligand binding is supported by observations made with single particle tracking (SPT) of EGFR to monitor receptor mobility, reviewed by¹⁷. To date, SPT of EGFR has largely relied on fluorescent labeling of an anti-EGFR antibody^{18,19}, Fab^{20,21}, or EGF ligand^{18,22–27}, or fluorescent protein fusion to EGFR^{28–31}. These studies established that EGFR exhibits heterogeneity with respect to mobility, with each study reporting that specific fractions of the receptor are immobile and/or confined. The remaining EGFR exhibited mobile behaviour, and in some cases directed movement, such as along filopodia²⁷. Extending these insights to resolve the regulation of EGFR confinement in relation to ligand-binding and signaling is currently an important priority.

Several SPT studies used broad perturbations, for example extraction of cholesterol or disruption of actin dynamics, finding that each impacts EGFR confinement¹⁷. Given the broad impact of these perturbations, the molecular mechanisms that establish the heterogeneous confinement of EGFR remain poorly understood. Some studies have suggested that EGFR confinement could result from formation of EGFR oligomers, either in the basal state favouring EGFR inactivation³² or in the ligand-bound state resulting in propagation of signaling beyond the activated EGFR dimer^{33–35}.

Association with other cell surface structures also controls EGFR confinement. CD82, which forms tetraspanin enriched nanodomains at the plasma membrane, contributes to EGFR confinement¹⁹, as does clathrin³¹, a well-known scaffold protein required for formation of clathrin-coated pits leading to receptor internalization^{36,37}. These studies indicate that the confinement of EGFR may result from both receptor-intrinsic (e.g. homo-oligomerization) as well as receptor-extrinsic (association with tetraspanins or clathrin) factors. However, the role of specific nanodomains in regulating EGFR confinement and signaling at the level of EGFR ligand binding has only begun to be examined.

Signaling by EGFR and other receptors is regulated by nanoscale organization of receptors and downstream transducers/effectors into specific nanodomains at the plasma membrane³⁸. This includes 200-400 nm nanodomains formed by assembly of tetraspanin proteins^{38,39}. The tetraspanins CD82, CD81, CD9 interact with EGFR and together with CD151^{40,41} may regulate EGFR signal transduction^{42–47}, by enrichment of signaling intermediates^{48–52} within tetraspanin domains. Moreover, ligand binding by EGFR leads to enhanced recruitment to clathrin-coated pits and subsequent receptor endocytosis³⁶. Clathrin-coated pits and endocytosis regulate more distal aspects of EGFR signaling such as Akt phosphorylation^{53–55}.

How engagement by EGFR in homo-oligomerization and/or recruitment to specific nanodomains each control receptor mobility and confinement, and how this impacts EGFR ectodomain conformation and ligand binding remains obscure. Here, we developed SPT methods to separately resolve the mobility of total and ligand-bound EGFR. This allowed us to establish a model in which the dynamic confinement within tetraspanin nanodomains imparts on a small subpopulation of EGFR enhanced ligand binding capacity. Upon EGF stimulation, ligand-bound EGFR is significantly more confined in a manner that is independent of tetraspanins and instead relies on both oligomerization and clathrin nanodomain confinement. We present a model whereby the tetraspanin resident EGFR is preferentially able to bind EGF, which then relocates out of tetraspanin nanodomains to other regions of the plasma membrane including clathrin nanodomains, supporting robust signal transduction.

Results

Distinct dynamics of ligand-bound and total EGFR

To resolve how ligand-bound and total EGFR may each exhibit heterogeneous properties and behaviour, we devised SPT approaches to separately study each category of receptor. To selectively label ligand-bound EGFR, we conjugated the EGF ligand directly to Cy3B (henceforth “ligand-bound EGFR”, **Fig 1A**). EGF-Cy3B elicited signaling indistinguishable from that triggered by unlabelled EGF (**Fig S1C**), indicating that fluorescence conjugation did not alter ligand binding. To selectively label total EGFR (regardless of ligand binding), we developed a Fab fragment from mAb108⁵⁶, which we conjugated to Cy3B (**Fig 1A**). Importantly, while full-length mAb108 reduces binding of EGF to EGFR⁵⁶, saturating concentration of the Fab fragment did not alter EGF-Cy3B binding (**Fig S1A-B**). This indicates that this Fab does not reduce EGFR ligand binding and can thus act as a reliable reporter of total EGFR (whether ligand-bound or not, henceforth “total EGFR”). These parallel labeling strategies for total EGFR (via Fab-Cy3B) and ligand-bound EGFR (via EGF-Cy3B) provide strong signal-to-noise for imaging in TIRF-M at 20 Hz (**Fig 1A**), ideal for SPT analyses.

Using this approach, we found that a large majority of (total) EGFR detected by Fab-Cy3B is mobile (**Fig. 1B**, left panel). The proportion of confined/immobile EGFR versus mobile EGFR changes only modestly upon addition of EGF, including up to the highest concentration of [EGF] tested (200 ng/mL or 33 nM, **Fig. S1E**). In contrast, EGF-bound EGFR (EGF-Cy3B) exhibits much more prominent confined and immobile fractions (**Fig. 1B**, right panel) relative to what was seen with total EGFR. We confirmed the validity of this SPT approach, as samples subject to fixation exhibited nearly complete confinement (**Fig. S1D**).

We also determined the diffusion coefficient (**Fig. 1C**) and confinement radius (**Fig. 1D**) of total EGFR (detected by Fab-Cy3B) and ligand-bound EGFR (detected by EGF-Cy3B). As expected, the mobile class of EGFR had a higher diffusion coefficient than the confined and immobile classes, for both total EGFR and ligand-bound EGFR. While EGF stimulation did not impact the proportion of total EGFR in the mobile class (**Fig. 1B**), EGF stimulation selectively increased the diffusion coefficient of the mobile cohort of total EGFR (**Fig. 1C**). At the same time, the diffusion coefficient of the mobile cohort of ligand-bound EGFR was substantially lower than that of the mobile fraction of total EGFR (**Fig. 1C**). This suggests that unliganded, mobile EGFR participates in small-scale interactions that restrict the diffusion coefficient of the mobile receptor yet do not cause outright confinement, and that EGF stimulation releases some receptors from such interactions to further increase the diffusion of this mobile fraction.

As the fraction of confined or immobile EGFR does not change substantially upon EGF stimulation (**Fig. 1B**), these results suggest that only a subset of total EGFR can bind EGF, even at very high levels of [EGF], as ligand-bound EGFR is significantly more confined or immobile. As EGFR binding is complex ⁴⁻⁹, we focused most experiments on EGF concentrations in the physiological (5-10 ng/mL) range, where we expect ~10-40% of EGFR binding sites occupied with ligand (**Fig. S1F**). At these conditions (5-10 ng/mL EGF), we observe that selective tracking of ligand-bound EGFR (via EGF-Cy3B) yields mostly confined or immobile EGFR, yet we do not observe a robust ligand-induced increase in EGFR confinement of total EGFR at 5-10 ng/mL EGF (compared to the 0 ng/mL condition, **Fig. 1B**).

This suggest two possibilities: (i) that ligand binding occurs selectively in EGFR that is pre-confined in the basal state, with continued confinement ligand-bound EGFR by the same mechanism, or (ii) that ligand binding to EGFR triggers confinement that is distinct from that of unliganded EGFR, yet is concomitant to loss of confinement of pre-confined EGFR. Hence, we next sought to define how specific protein-driven nanodomains contribute to EGFR confinement in the basal and EGF-stimulated state, focusing on the effect of 10 ng/mL EGF treatment.

Systematic analysis of nanodomain enrichment of EGFR at the cell surface

The distribution of EGFR within various plasma membrane nanodomains has been examined previously (reviewed in ^{38,57}). However, few studies have studied EGFR enrichment in more than one candidate nanodomain at a time and in the same cell model used to study EGFR mobility by SPT, making conclusions about the relationship of confinement and nanodomain enrichment challenging. Hence, we used labeling strategies that allowed detection of total EGFR (via Fab-Cy3B) alongside simultaneous labeling of multiple nanodomain compartment markers, such as tetraspanins using specific antibodies (**Fig. S2B**).

This imaging was coupled to automated detection of EGFR via a Gaussian-based modeling approach ^{53,58-60}, which allows measurement of the levels of a particular marker (EGFR or secondary 'nanodomain' channels) at the position of the detected EGFR object. To determine specific detection of secondary 'nanodomain' channels within EGFR objects, background overlap was determined by repeating measurements after the position of the EGFR image had been randomized. This approach revealed that caveolin-1 and flotillin-1 are not significantly detected in EGFR objects under either basal or EGF-stimulated conditions (**Fig. S3A, S3F-G**). In contrast, each of the tetraspanins CD81 (**Fig. 2**), CD82 (**Fig. S4A**) and CD151 (**Fig. S4B**) as well as clathrin (**Fig. 2A, S3, S4, S5**) were significantly detected within EGFR objects in the basal and EGF-stimulated condition (**Fig. S3B-E**).

Using this approach and subtracting background (random) overlap allowed assessment of the effect of EGF stimulation on EGFR overlap with tetraspanin and clathrin plasma membrane nanodomains (**Fig. 2**). EGF did not impact the level of CD81 associated with EGFR objects (**Fig. 2B**), but reduced that of CD82 (**Fig. 2C**), or CD151 (**Fig. 2D**). In contrast, EGF stimulation robustly increased the level of clathrin detected within EGFR objects (**Fig. 2E**). As this approach reveals the average levels of tetraspanins or clathrin associated with EGFR objects, these results could either indicate that upon EGF stimulation, individual EGFR objects associate with smaller-scale assemblies of CD82 and CD151 (e.g. nanodomains to small oligomers/clusters) or that a subset of EGFR disengages completely from tetraspanin association. To resolve this, we used a complementary method of analysis that determines the probability of overlap of EGFR with a secondary marker, considering only the position of EGFR and secondary channel objects but not their intensities^{61,62}. This analysis showed significant association of EGFR with each of CD81 (**Fig. 2F**), CD82 (**Fig. 2G**) and CD151 (**Fig. 2H**), and notably this overlap of EGFR and each tetraspanin was not affected by EGF stimulation.

These results imply that there is no detectable change in the fraction of EGFR associated with tetraspanins upon EGF stimulation, but that EGF stimulation triggers a decrease in the size of CD82 and CD151 assemblies associated with EGFR. This in turn suggests that there are two scales of EGFR association with CD82 and CD151 – with larger scale assemblies, perhaps tetraspanin nanodomains preferred in the basal state and smaller scale assemblies that are retained upon EGF stimulation. We observed that EGF-stimulation induces robust overlap with clathrin (**Fig. 2E**), reflecting recruitment of EGFR to clathrin coated pits, which are large nanodomains expected to confine or immobilize EGFR. This interpretation of an apparent shift of enrichment of a subset of EGFR from one nanodomain comprised of larger-scale tetraspanin assemblies to another larger-scale nanodomain (clathrin) upon EGF stimulation is consistent with our observation that EGF stimulation does not elicit a robust change in the overall fraction of EGFR in each of the mobility classes. This suggests a model in which prior to ligand-binding, a subset of EGFR is pre-confined within tetraspanin nanodomains, and that following ligand binding, ligand-bound EGFR exits tetraspanin nanodomains while retaining small-order tetraspanin association, and is rapidly recruited and confined by another mechanism, which may include clathrin nanodomains.

Distinct confinement requirements for non-ligand bound versus ligand-bound EGFR

The association of small scale tetraspanins assemblies with EGFR is expected to reveal a role for tetraspanins in regulating the diffusion of mobile EGFR. In contrast, EGFR association with larger scale tetraspanin assemblies (e.g. in nanodomains) is expected to impact the fraction of EGFR that is confined or immobile. Our SPT methods are thus ideally suited to resolve how tetraspanins may distinctly modulate the mobility of ligand-bound and non-liganded EGFR.

We examined the effects of silencing of several tetraspanins reported to have some interaction with EGFR or with one another (**Fig. S2A-B**), on the mobility of EGFR as assessed by SPT. Silencing of CD81 significantly reduced the fraction of Fab-Cy3B tracks classified as immobile or confined, while increasing the fraction of mobile tracks in the basal state (**Fig. 3A**). Silencing of CD81 appeared to have similar yet more modest effect on Fab-Cy3B tracks in the EGF-stimulated state (**Fig. 3B**), and was without effect on the fraction of EGFR in each mobility cohort of ligand-bound EGFR (**Fig. 3C**). Similar results were obtained in MDA-MB-231 cells (**Fig. S5**). Consistent with our localization analyses (**Fig. 2**), this suggests that CD81 plays an important role in the confinement or immobilization of unliganded EGFR as a result of recruitment of this cohort of EGFR into larger-scale tetraspanin assemblies.

Interestingly, silencing CD81 also resulted in an increase in the diffusion coefficient of the mobile fraction of total EGFR (detected via Fab-Cy3B), both in the basal (**Fig. 3D**) and in the EGF-stimulated condition (**Fig. 3E**), but not for the ligand-bound EGFR (**Fig. 3F**). Silencing of CD82, CD9 or CD151 did not alter the proportion of EGFR within the mobility classes (**Figs. S6A-C, S7A-C, S8A-C**). However, silencing of each of CD82, CD9 and CD151 increased the diffusion coefficient of the mobile fraction, both for

unliganded EGFR and ligand-bound EGFR (**Fig. S6D-F, S6D-F, S8D-F**). This indicates that in addition to a specific role for CD81 in establishing a subset of confined/immobile EGFR in the unliganded state, all tetraspanins contribute in some capacity to decreasing the diffusion of mobile EGFR. This is consistent with the observation that EGFR remains associated with small-scale tetraspanin assemblies upon EGF stimulation (**Fig. 2**). Concomitant silencing of all four of these tetraspanins was also without effect on the mobility of ligand-bound EGFR, detected via EGF-Cy3B tracking (**Fig. S9**), indicating that the lack of effect of silencing of each tetraspanins on the confinement of ligand-bound EGFR was unlikely the result of redundancy among these four tetraspanins. As tetraspanin silencing did not impact the fraction of confined or immobile ligand-bound EGFR, confinement of EGFR in larger-scale tetraspanin assemblies (tetraspanin nanodomains) may not be compatible with ligand-bound EGFR.

These results support a model in which the cohort of non-ligand-bound EGFR are pre-confined in a CD81-dependent manner within tetraspanin nanodomains that may contain CD81, CD82, CD9 and CD151, where EGFR may exhibit preferential association with EGF. We thus next examined if EGFR within tetraspanin nanodomains may exhibit preferential binding to EGF. To do so, we examined if short times of incubation with Cy3B-EGF would result in preferential labeling within tetraspanin domains compared to labeling by Fab-Cy3B (total EGFR). Following labeling with Fab-Cy3B or EGF-Cy3B, labeling of CD82, imaging by TIRF-M and detection of Cy3B puncta, we used an arbitrary but systematic threshold to define CD82-positive Cy3B puncta. Stimulation for 15s resulted in EGF-Cy3B puncta that were significantly enriched within CD82 structures compared to Fab-Cy3B puncta (**Fig. 4A**). This experiment indicates that EGF exhibits preferential association with EGFR within tetraspanin nanodomains relative to the entire pool of total EGFR within the plasma membrane.

The preferential association of EGF with EGFR detected alongside tetraspanins suggests that tetraspanins may regulate EGFR ligand binding. Silencing CD81 alone or all four tetraspanins in combination significantly reduced EGF-Cy3B cell surface binding (**Fig. 4B**) relative to cell surface EGFR levels (**Fig. S10**). mAb806 is a conformationally-sensitive EGFR antibody that does not bind to tethered, closed EGFR or ligand-bound conformation^{14,63–65}. Thus, a change in mAb806 binding to EGFR may reflect a change in conformation of the EGFR ectodomain, although the extent of mAb806 binding may not be directly proportional to ligand affinity. Tetraspanin silencing elicited a small but significant increase in the cell-surface binding of mAb806 relative to cell surface EGFR levels (**Fig. 4C**). Hence, tetraspanins associate with EGFR at different scales of assembly, including outright confinement that is selective for the non-ligand bound EGFR, and tetraspanins regulate EGFR ectodomain conformation and enhance EGFR ligand binding.

As EGF stimulated enrichment of EGFR in clathrin labelled structures (**Fig. 2A,E**), we next examined if the confinement of ligand-bound EGFR was functionally dependent on clathrin heavy chain (henceforth clathrin), the core protein for formation of clathrin-coated pits. Silencing clathrin did not impact the proportion of total EGFR (detected via Fab-Cy3) in each mobility class in the absence of EGF ligand (**Fig. 5A**). In contrast, clathrin silencing increased the proportion of total EGFR exhibiting mobile behaviour in the EGF-stimulated state (**Fig. 5B**) as well as that of ligand-bound EGFR (detected via EGF-Cy3B) (**Fig. 5C**).

In addition, clathrin silencing resulted in a significant increase in the diffusion coefficient of total EGFR in the absence (**Fig. 5D**) or presence (**Fig. 5E**) of EGF stimulation, and of ligand bound EGFR (**Fig. 5F**), as well as a modest but significant increase in the confinement radius of confined but not immobile EGFR, selectively in the presence of EGF stimulation (**Fig. 5G-I**). This is consistent with the existence of highly transient clathrin assemblies that undergo rapid abortive turnover without formation of bona fide clathrin-coated pits⁶⁶, which become further de-stabilized under clathrin silencing conditions where clathrin abundance is limiting. These abortive clathrin assemblies that are transient (some with lifetimes <3-5s) are expected to impact the diffusion of mobile EGFR without leading to outright receptor confinement or immobilisation that occurs within bona fide clathrin-coated pits. Nonetheless, while the high sensitivity of these SPT measurements reveals unprecedented insight into the role of clathrin in transient association

with mobile EGFR, these results reflect a preferential role for clathrin in recruitment of EGFR to immobile and confined receptor fractions when ligand-bound.

Our observations that ligand-bound EGFR remains associated with small-scale tetraspanin assemblies predicts that EGF stimulation would result in increased association of tetraspanins with clathrin, given the recruitment of EGFR to clathrin structures upon EGFR stimulation (**Fig. 2**). To investigate this, we focused on CD81 and performed additional analysis on the images presented in Figure 2 to detect the overlap of CD81 objects with clathrin. As predicted, EGF stimulation triggered an increase in the intensity of clathrin within CD81 puncta (**Fig. 5J**). To determine if the increase of clathrin associated with CD81 objects correlated with EGFR recruitment to these same structures, we analyzed these images using conditional colocalization analysis⁶². This analysis allowed us to determine whether the probability of colocalization between CD81 and clathrin puncta increased when they also colocalized with EGFR. Like the colocalization analysis in Fig. 2F-H, this analysis was irrespective of object intensity. Using this approach, the probability of overlap of clathrin and CD81 puncta was found to be higher in the condition of additional overlap with EGFR than in its absence (**Fig. 5K**). Hence, consistent with the association of EGFR with small-scale assembly CD81 and other tetraspanins, these results indicate that CD81 and EGFR exhibit co-recruitment into clathrin-coated pits upon EGF stimulation.

Together, our results indicate that upon stimulation at 10 ng/mL, EGF binding occurs preferentially for EGFR pre-confined within tetraspanin nanodomains, and that ligand binding triggers the rapid loss of EGFR from tetraspanin confinement yet triggers confinement of ligand-bound EGFR by other mechanisms that include EGFR recruitment to clathrin-coated pits.

Quantitative modeling recapitulates EGFR nanodomain confinement measures

Our results suggest larger-scale tetraspanin domains can confine unliganded EGFR and promote EGF binding, and that once ligand-bound, EGFR has reduced dependence on tetraspanins for confinement and instead can be confined by clathrin nanodomains. This sequence of EGFR states is described by a model with four distinct states in **Fig. 6A**: unliganded EGFR can enter and exit larger-scale tetraspanin assemblies (tetraspanin domains) where the receptor becomes confined; ligands can bind unliganded EGFR confined in tetraspanin domains, allowing EGFR exit; ligand-bound EGFR can be confined by clathrin domains and/or oligomerization; and ligand-bound EGFR in clathrin domains can be removed from the cell membrane (e.g. via clathrin endocytosis).

To further explore EGFR dynamics, we developed a spatial, stochastic, agent-based quantitative model, consistent with the description of **Fig. 6A**, that includes EGFR diffusion on the membrane, ligand binding, entry into and exit from tetraspanin and clathrin domains, and removal from the membrane. The model simulates individual EGFR as they diffusively explore a membrane region containing both tetraspanin and clathrin domains. Energy barriers impede unliganded EGFR entry and exit from tetraspanin domains, and ligand-bound EGFR entry and exit from clathrin domains. In this model, EGFR may only become ligand bound inside tetraspanin domains, and we only consider EGFR association within larger-scale tetraspanin assemblies that results in confinement, but not smaller-scale association of EGFR with tetraspanins.

This model determines the fraction of EGFR confined within each type of nanodomain at different levels of ligand binding (expressed as ligand binding rate, s^{-1} , which is a term proportional to ligand concentration) (**Fig. 6B**). This quantitative model recapitulates the experimental nanodomain confinement behaviour of EGFR given energy barrier parameters that result in relatively slow EGFR entry and exit from tetraspanin domains (mean entry time $83s \pm 8s$) (**Fig. 6B**). The proportion of all EGFRs (i.e. both unliganded and ligand-bound) and ligand-bound EGFR that are confined are both largely independent of the EGF binding rate to unliganded EGFR in tetraspanin domains, with the fraction of all EGFR that is confined much lower than the fraction of ligand-bound EGFR that is confined. This model also shows that as the EGF binding rate increases, the fraction of EGFR confined in tetraspanin

nanodomains substantially decreases and the fraction of EGFR in clathrin domains substantially increases, which is again consistent with the EGF-stimulated depletion of EGFR from tetraspanin nanodomains and enrichment of EGFR within clathrin nanodomains observed experimentally (**Fig. 2**). This modeling approach thus supports our observations that EGFR undergoes a shift the molecular mechanism of confinement upon EGF stimulation, without an apparent shift in the total fraction of EGFR that is confined and/or immobile.

Tetraspanins regulate EGFR ectodomain conformation and EGFR signaling.

The confinement of unliganded EGFR in tetraspanin nanodomains and the requirement of tetraspanins for ligand binding suggest that tetraspanin nanodomains control EGFR signaling. We examined the effect of perturbation of specific tetraspanin proteins on EGF-stimulated EGFR phosphorylation at low doses of EGF (10 ng/mL). In all cases, we consider the levels of phosphorylated EGFR relative to cell surface EGFR (**Fig. S10**). Silencing of CD81 does not alter EGF-stimulated EGFR phosphorylation at Y1068 Y1173 and Y845, nor that Akt and Erk that depend on EGFR Y1068 and/or Y1173 phosphorylation (**Fig. 7A-B**). That silencing CD81 elicits a robust reduction of ligand binding (**Fig. 4B**) yet has a modest effect of EGF-stimulated EGFR phosphorylation suggests that other mechanisms are engaged to propagate signaling in tetraspanin-silenced conditions.

We thus considered the regulation and role of EGFR oligomerization upon EGF stimulation, which contributes to lateral signal propagation of EGFR to unliganded receptors^{33–35}. Oligomerization occurs via face-to-face interactions of EGFR dimers, involving the unliganded subunit within ligand-bound dimer and another unliganded EGFR dimer³⁵. Hence, while oligomers form at lower EGF concentrations (~10 ng/mL) in which ~10-30% EGFRs are ligand bound (**Fig. S1F**), oligomers are disrupted at higher [EGF] due to depletion of unliganded EGFRs³⁵. At 100 ng/mL EGF (10 ng/mL EGF-Cy3B supplemented with 90 ng/mL unlabelled EGF) where 70-90% of ligand-binding sites are occupied (**Fig. S1F**), ligand-bound EGFR is significantly less confined than at 10 ng/mL EGF-Cy3B alone (**Fig. 7C**), while EGFR diffusion coefficient (**Fig. 7D**) and confinement radius (**Fig. 7E**) was indistinguishable. This is consistent with the formation of EGFR oligomers at low [EGF] that together with clathrin nanodomains contribute to confinement of ligand-bound EGFR.

This further suggests that loss of CD81, which substantially reduces EGF binding, may not impact EGF-stimulated EGFR Y1068 phosphorylation because of enhanced contribution of EGFR oligomerization to signaling upon CD81 silencing. To probe this possibility directly, we examined the effect of CD81 silencing on EGFR Y992 phosphorylation. In contrast to other sites on EGFR, the phosphorylation of Y992 occurs with a strong preference in trans between dimers in an oligomer, given the steric constraints of phosphorylation of this kinase domain-proximal residue in cis within a dimer unit³⁵. Silencing of CD81 significantly increased EGF-stimulated Y992 EGFR phosphorylation (**Fig. 7F**). This supports a model in which loss of CD81 reduces EGFR ligand binding affinity, while also increasing the propensity of a smaller number of ligand-bound EGFR dimers to form oligomers. This is in turn consistent with our observation of small-order assemblies of EGFR and tetraspanins that may thus function to restrict EGFR oligomerization and lateral signal propagation, in addition to promoting ligand binding.

We next sought to further probe the mechanisms that trigger confinement of ligand-bound EGFR. To do so, we examined the effect of treatment with the EGFR tyrosine kinase inhibitor erlotinib. In addition to inhibition of the kinase activity of EGFR, erlotinib binding to the receptor elicits conformational rearrangement that favors formation of EGFR asymmetric kinase domain dimers which disfavour oligomerization³² and increase ligand-binding affinity⁶⁷. Consistent with this, cells treated with erlotinib exhibited an decreased binding of the conformationally-sensitive mAb806 (**Fig. 8A**), as had been reported previously for other type I TKIs that bind the active kinase conformation¹⁴.

As erlotinib alone increases ligand binding affinity⁶⁷, and disrupts oligomer formation, we expect that erlotinib treatment will result in higher mobility of ligand-bound EGFR. Consistent with this, erlotinib treatment significantly reduced the confinement of ligand-bound EGFR (**Fig. 8B**). In contrast, erlotinib

was without effect on the confinement of total EGFR, either in the absence or presence of ligand (**Fig. 8C**). Similar effects were observed with other EGFR tyrosine kinase inhibitors (**Fig. S11**). Erlotinib also did not impact the diffusion coefficient (**Fig. 8E-F**) or confinement radius (**Fig. 8H-I**) of total EGFR, yet increased the diffusion of ligand-bound EGFR in confined and mobile receptor cohorts (**Fig. 8G**) and increased the confinement radius of confined EGFR (**Fig. 8I**). Similar results were obtained with erlotinib in other cell lines (**Fig. S12**). These results indicate that erlotinib treatment triggers a conformational change throughout the cell surface pool of EGFR that increases the receptor's ligand binding affinity, mimicking that which is typically restricted to EGFR confined within tetraspanin nanodomains in the absence of erlotinib. Following ligand binding, ligand-bound remain highly mobile, as erlotinib impairs EGFR oligomerization but not dimerization³² and prevents engagement with clathrin-coated pits.

Discussion

We resolved that only a minor fraction of total EGFR has preferential ligand binding at a physiological concentration of EGF, and that ligand-binding occurs preferentially in EGFR within tetraspanin nanodomains. The tetraspanin CD81 is required for recruitment of EGFR to confined and immobile fractions in the basal state, while confinement of ligand-bound EGFR was dependent on clathrin and EGFR oligomerization. We also show that loss of CD81 leads to a reduction in ligand binding by EGFR, which modulates EGFR signaling.

Distinct confinement mechanisms of non-ligand and ligand-bound EGFR

EGFR is capable of oligomerization, both in the basal state³² and upon binding ligand³⁴. Oligomers of EGFR could be mobile yet have a reduced diffusion coefficient for smaller oligomers or exhibit outright confinement for sufficiently large oligomers. Our SPT analysis revealed that only a fraction of total EGFR classified as confined or immobile in the basal state. Importantly, erlotinib treatment results in the formation of dimers that disrupts the auto-inhibitory EGFR oligomers formed solely by unliganded receptors observed in the basal state in some cells³². Erlotinib treatment did not alter the confinement of non-ligand bound EGFR (**Fig. 8**), indicating that the in the basal state, confined and/or immobile EGFR subpopulations we observe are likely not the result EGFR homo-oligomerization. We observed similar effects in ARPE-19 non-cancerous cells of epithelial origin, as well as MDA-MB-231 and SUM-149PT breast cancer cells (**Fig. S12**). Hence, EGFR basal oligomers may occur preferentially in specific cell types. Nonetheless, our data show a role for CD81 in the recruitment of EGFR within confined and immobile fractions in the basal state.

Our SPT data shows that ligand-bound EGFR is substantially more confined and/or immobile than non-ligand bound EGFR (**Fig. 1B**). Furthermore, we found that the fraction of ligand-bound EGFR within each mobility class is insensitive to perturbation of tetraspanins (**Fig. 3** and **Fig. S5-9**) but instead impacted by perturbation of clathrin (**Fig. 5**). These results indicate that the molecular basis of confinement of the ligand-bound EGFR is distinct from the non-ligand-bound receptor, and partly dependent on clathrin-coated pits. As formation of EGFR oligomers require a pool of unliganded EGFR³⁵, and since ligand-bound EGFR exhibited higher mobility upon treatment with 100 ng/mL EGF (depleting the unliganded EGFR pool) compared to 10 ng/mL EGF (**Fig. 7C**), this suggests that EGFR oligomers contribute to confinement of ligand-bound EGFR at physiological [EGF]. EGFR homo-oligomers can range from 18.5 nm (tetramer) to 50 nm (12-mer) in length³², which is smaller than the ~100-200 nm diameter of tetraspanin nanodomains and clathrin coated pits, yet consistent with receptor confinement. Hence, our results are consistent with the high degree of confinement of ligand-bound EGFR resulting from both EGFR oligomerization and/or recruitment into clathrin coated pits.

Regulation of EGFR signaling by tetraspanin nanodomains.

A common view of tetraspanin nanodomains is that different tetraspanins co-assemble into common structures and that some tetraspanins are functionally redundant (e.g. CD9/81 and CD151)^{38-40,68-70},

although this is not the case for all tetraspanins as CD53 and CD81 assemble into distinct structures⁷¹. The tetraspanins CD82, CD81, and CD9 interact with EGFR^{40,41} (**Fig. S2A**), and previous reports, based largely on overexpression approaches, suggest that tetraspanins may regulate EGFR signaling^{42–47}. Other studies showed that silencing CD82 altered EGFR mobility and Erk activation upon stimulation with supra-physiological EGF concentrations¹⁹. These results are consistent with that of this study in that tetraspanin proteins regulate receptor signaling^{38,57}. We reveal a selective role for tetraspanins in confinement of unliganded EGFR, and regulation of EGFR ligand binding. Hence, while tetraspanins may also regulate EGFR membrane traffic, in particular when overexpressed, this work reveals a novel role for tetraspanin proteins at endogenous expression levels in the regulation of EGFR ligand binding affinity.

Our experiments also reveal that in addition to the outright confinement of EGFR in the basal state that was dependent on CD81 (**Fig. 3**), silencing of all tetraspanins examined also increased the diffusion coefficient of mobile EGFR in the basal (unliganded) or ligand-bound states (**Fig 3, S5-9**). This suggests that EGFR also associates with some tetraspanins in smaller protein assemblies that nonetheless retain mobile behaviour. We also observe that EGFR association with CD81 is retained following EGF stimulation (**Fig. 2B**), which is consistent with the co-enrichment of EGFR and CD81 within clathrin-coated pits following EGF stimulation (**Fig. 5J-K**). This in turn suggests that smaller-order EGFR-CD81 assemblies are retained upon ligand binding or that clathrin-coated pits may form at pre-determined specific sites of CD81-positive tetraspanin nanodomains, such that CD81 becomes dispensable for confinement of ligand-bound EGFR. Nonetheless, our results show that CD81 is selectively required for the confinement of a small cohort of unliganded EGFR.

Regulation of EGFR ectodomain conformation within tetraspanin nanodomains

Our results show that tetraspanins regulate EGFR confinement and signaling, sequestering a minor subpopulation of EGFR alongside factors that promote high affinity ligand-binding with tetraspanin nanodomains. This model is consistent with many previous studies that show that the ligand-binding of EGFR is regulated, and that EGFR exhibits subpopulation of receptors at the cell surface with distinct affinities^{4–10}.

Silencing CD81 and other tetraspanins resulted in loss of ligand binding (relative to cell surface EGFR) (**Fig. 4B**) yet was without effect on EGF-stimulated EGFR autophosphorylation of Y1068 and Y1173 (**Fig. 7A-B**). The ability of a ligand-bound active EGFR dimers to oligomerize with unliganded EGFR dimers extends the phosphorylation of EGFR laterally, with phosphorylation of the C-terminal tails occurring in trans between dimer units in an oligomer³⁵. That the substantial loss of ligand binding by EGFR upon silencing of CD81 and other tetraspanins does not impact EGFR phosphorylation on Y1068 indicates that loss of tetraspanins may further promote oligomerization-dependent signaling present in unperturbed cells. Consistent with this, silencing of CD81 increased EGF-stimulated Y992 phosphorylation that is supported largely by phosphorylation in trans within an EGFR oligomer, and not in cis within a single EGFR dimer³⁵.

Collectively, this suggests that CD81 and possibly other tetraspanins regulate two aspects of EGFR signaling: (i) enhancement of direct EGFR binding to EGF, likely restricted to the confined fraction of EGFR in larger-scale tetraspanin assemblies and (ii) suppression of formation of signaling oligomers of EGFR, perhaps as a result of small-scale EGFR-tetraspanin assemblies that are mobile. This reveals that tetraspanins have a key role in control of receptor signaling, both in terms of its magnitude and sensitivity, but also in modulation of relative phosphorylation of specific EGFR tyrosine residues.

Following EGF binding that occurs preferentially in tetraspanin nanodomains, EGFR undergoes recruitment to clathrin structures at the cell surface, leading to eventual internalization of EGFR. While clathrin perturbation did not impair EGF-stimulated EGFR phosphorylation, clathrin structures are enriched in downstream signaling proteins and modulate Akt signaling by EGFR^{53,54,59,72} suggesting that

clathrin-dependent regulation of Akt occurred subsequent to EGFR phosphorylation, and thus subsequent to tetraspanin-dependent regulation of EGFR ligand binding.

While the regulation of transition from a tethered, low affinity conformation of the ectodomain to an untethered conformation has been suggested from molecular dynamic simulations and study of EGFR mutants^{14,63,73}, the cellular processes that contribute to the regulation conformational transitions were poorly understood. Here, we reveal that the ectodomain conformation of EGFR may be gated by specific tetraspanins in a manner consistent with transition from a tethered, low affinity EGFR to a higher affinity, untethered EGFR ectodomain in a spatially-restricted manner within tetraspanin nanodomains. This work reveals a new mechanism for the regulation of EGFR conformation and ligand binding within specific subpopulations of EGFR, which has important impact on the understanding EGFR regulation of cell physiology, as well as the role of EGFR as a driver of tumor progression.

Materials and Methods

Materials. Antibodies used to detect specific proteins were obtained as follows: CD82 from Cedarlane labs (clone 33, Burlington, ON, Canada), CD151 and flotillin-1 from Sigma Aldrich (Mississauga, ON, Canada), phosphorylated EGFR (pY1068), caveolin-1 from Cell Signaling Technology (Danvers, MA). Phorbol 12-myristate 13-acetate (PMA) was obtained from Abcam (Cambridge, MA). Erlotinib, gefitinib, and lapatinib were obtained from MedChemExpress (Monmouth Junction, NJ). Fluorophore-conjugated or horseradish peroxidase (HRP) secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). mAb806 was previously described^{14,63–65}.

Cell Culture. Wild-type human retinal pigment epithelial cells (ARPE-19; RPE cells herein), and ARPE-19 cells stably expressing clathrin light chain fused to enhanced GFP (RPE-GFP-CLC) were previously described^{58,74,75}. Cells were cultured in DMEM/F12 (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), 100 U/ml penicillin, and 100 µg/ml streptomycin (Life Technologies) at 37°C and 5% CO₂.

Single Particle Labeling and Tracking of EGFR. The Fab fragment was generated from mAb108⁵⁶. The mAb108 hydridoma was obtained from American Type Culture Collection (ATCC, catalog. HB-9764, Manassas, VA). Generation of Fab fragments and Fab labeling with Cy3B was performed by AbLab Biologics, to produce Fab-Cy3B (University of British Columbia, BC, Canada). EGF-Cy3B was generated using NHS-Cy3B (Cytiva, Marlborough, MA) conjugated to recombinant human EGF (Gibco, ThermoFisher Scientific), using 1:1 labeling stoichiometry as described previously⁶⁰. To label single particles (unless otherwise indicated), cells were incubated with either 10 ng/mL EGF-Cy3B for 5 min prior to imaging (to selectively label and track ligand-bound EGFR), or with 50 ng/mL Fab-Cy3B (to label and track total EGFR) for 10 min followed by washing to remove unbound antibodies, in media lacking EGF or following 5 min of stimulation with 10 ng/mL unlabelled recombinant EGF. Time-lapse imaging was performed using total internal reflection fluorescence (TIRF) microscopy using a Quorum (Guelph, ON, Canada) Discovery instrument, comprised of a Leica DMI8 microscope equipped with a 63×/1.49 NA TIRF objective with a 1.8× camera relay (total magnification 108×). Imaging was done using 561 nm laser illumination and 620/60 nm, emission filters and acquired using an iXon Ultra 897 EM-CCD (Spectral Applied Research, Andor, Toronto, ON, Canada) camera at a framerate of 20 Hz, for total length of 8 s of time-lapse (250 frames). Single particles labelled with Cy3B were detected and tracked as described⁷⁶, and the motion types, diffusion coefficients and confinement radii were determined as previously described^{77,78}.

EGFR nanodomain microscopy and analysis. After treatments as indicated cells were fixed 4% paraformaldehyde for 30 min, followed quenching of fixative in 100 mM glycine, cell permeabilization in 0.1% Triton X-100 (all solutions made in PBS), and then blocking in Superblock Blocking Buffer (Thermo Fisher Scientific). Subsequently, cells were stained with primary and secondary antibodies as indicated, and then subjected to imaging using TIRF microscopy using a Quorum (Guelph, ON, Canada) Discovery instrument, comprised of a Leica DMI8 microscope equipped with a 63×/1.49 NA TIRF objective with a 1.8× camera relay (total magnification 108×). Imaging was done using 405-, 488-, 561-, and 637-nm laser illumination and 450/55, 525/50, 620/60, and 700/75 emission filters and acquired using a Zyla 4.2Plus sCMOS camera (Hamamatsu).

Systematic, unbiased detection and analysis of diffraction-limited EGFR objects in fixed cells (E.g. Fig. 2), was done as previously described^{58,60}, using custom software developed in Matlab (Mathworks Corporation, Natick, MA), as described in^{53,75}.

Briefly, for analyses involving intensity (**Fig. 2B-E, 4A, 5J, S3**), diffraction-limited EGFR objects (resulting from labelling by Fab-Cy3B or EGF-Cy3B) were detected using a Gaussian-based model method to approximate the point-spread function of EGFR ('primary' channel). The TIRF intensity corresponding to various proteins in a 'secondary' (or 'tertiary') channel (eGFP-clathrin, CD82, caveolin, flotillin within EGFR objects) was determined by the amplitude of the Gaussian model for the appropriate

fluorescence channel for each object detected in the ‘primary’ channel. As such, the measurements of fluorescently labelled proteins within EGFR represent their enrichment relative to the local background fluorescence in the immediate vicinity of the detected EGFR objects.

For colocalization analyses not involving intensity (**Fig. 2F-H and Fig. 5K**), diffraction-limited objects in all channels (EGFR and others) were detected as described above for EGFR. Object colocalization was then assessed based on the nearest neighbor distances between the detected object locations, as described in ⁶¹, using a colocalization radius of 3 pixels. For conditional colocalization analysis (Fig. 5K), colocalization between CD81 and clathrin was assessed similarly, but after subdividing the CD81 and clathrin objects based on their colocalization with EGFR, as described in more detail in ⁶².

siRNA gene silencing. siRNA transfections were performed using custom-synthesized siRNAs using RNAiMAX transfection reagent (Life Technologies) as per manufacturer’s instructions. Briefly, each siRNA was transfected at a concentration of 220 pmol/l with transfection reagent in Opti-MEM Medium (Life Technologies). Cells were incubated with the siRNA complexes for 4 h, after which cells were washed and replaced in regular growth medium. siRNA transfections were performed twice (72 and 48 h) before each experiment. Sequences used were as follows (sense): control (non-targeting): CGU ACU GCU UGC GAU ACG GUU; clathrin heavy chain (clathrin): GGG AAU AGU UUC AAU GUU U; CD82: CCC AUC CUG ACU GAA AGU AUU; CD9: CCA CAA GGA UGA GGU GAU UUU; CD81: CCU CAG UGC UCA AGA ACA AUU; CD151: CCC AUC CUG ACU GAA AGU AUU.

Western blotting. After transfection, treatment with inhibitors, and/or stimulation with EGF, whole-cell lysates were prepared using in Laemmli sample buffer (LSB; 0.5 M Tris, pH 6.8, glycerol, 10% SDS, 10% β -mercaptoethanol, and 5% bromophenol blue; all from BioShop, Burlington, Canada) supplemented with a protease and phosphatase inhibitor cocktail (1 mM sodium orthovanadate, 10 nM okadaic acid, and 20 nM Protease Inhibitor Cocktail, each obtained from BioShop). Lysates were then heated at 65°C for 15 min and passed through a 27.5-gauge syringe. Proteins were resolved by glycine-Tris SDS-PAGE followed by transfer onto a polyvinylidene fluoride membrane; as previously described ⁷⁹. Western blot signals to detect the intensity corresponding to phosphorylated proteins (e.g., pEGFR) were obtained as previously described ⁵⁸ by signal integration in an area corresponding to the appropriate lane and band for each condition. This measurement is then normalized to the loading control (e.g., actin) signal.

Quantitative modeling. EGFR diffuses on a square, two-dimensional lattice with diffusivity $D = 0.2 \mu\text{m}^2/\text{s}$ ⁸⁰. The square region is $0.2 \mu\text{m} \times 0.2 \mu\text{m}$ with periodic boundary conditions. The lattice has sites separated by $\Delta x = 0.002 \mu\text{m}$, and the timestep used is $\Delta t = 5 \times 10^{-6} \text{ s}$, determined by the two-dimensional requirement that $\Delta t = (\Delta x)^2/(4D)$ ⁸¹. Each timestep, the EGFR attempts to step to one of the four nearest-neighbor lattice sites. If there is no energy barrier, the step is successful; if there is an energy barrier between the two lattice sites, the step is successful with a probability determined by the Metropolis criterion of $P_{\text{success}} = \exp[-\Delta E/(k_B T)]$, where ΔE is the energy barrier height ⁸².

The square membrane has 10 circular tetraspanin domains and 10 circular clathrin domains, each of which do not overlap other tetraspanin or clathrin domains. At the beginning of each EGFR trajectory these 20 domains are randomly positioned. Each domain has a radius of $0.0056 \mu\text{m}$, so that each domain is approximately 100 nm^2 . The energy barrier for an unliganded EGFR to enter a tetraspanin domain is $\Delta E_{\text{et}} = 11.5 k_B T$, for an unliganded to leave a tetraspanin $\Delta E_{\text{lt}} = 13 k_B T$, for a liganded EGFR to enter a clathrin domain $\Delta E_{\text{ec}} = 1 k_B T$, and for a liganded EGFR to leave a clathrin domain $\Delta E_{\text{lc}} = 4.5 k_B T$. These energy barriers have been selected to provide EGFR confinement consistent with experimental measurements. Energy barriers are not encountered for transitions of liganded EGFR into and out of tetraspanin domains and of unliganded EGFR into and out of clathrin domains.

Unliganded EGFR in a tetraspanin domain become ligand-bound at a rate that is varied (the ‘EGF binding rate’ in Fig. 6B). Liganded EGFR in a clathrin domain are removed from the membrane at a rate of 0.05 s^{-1} . EGFR begin each simulation without ligand and outside tetraspanin and clathrin domains. The fraction of time until EGFR removal that each individual EGFR trajectory is liganded and unliganded within

tetraspanin and clathrin domains is tracked. The fraction of time after ligand binding that each individual EGFR trajectory is within a clathrin domain is also tracked. The average EGFR confinement values, overall and ligand-bound, are determined by weighting the fractions by the time until EGFR removal from the membrane, as the likelihood of experimental observation of an EGFR is proportional to its lifetime on the membrane.

Statistical analysis. All measurements were subjected to one-way or two-way ANOVA followed by Tukey post-test with a threshold of $p < 0.05$ for statistically significant differences between conditions.

Acknowledgements

Funding for this research was provided by a Project Grant (PJT-156355) from the Canadian Institutes of Health Research (CIHR) to C.N.A. and G.D.F., and a New Investigator Award from the Canadian Institutes of Health Research (CIHR), Funding from Ryerson University, as well as an Early Researcher Award (Ontario Ministry of Research, Innovation and Science) to C.N.A. A.I.B. was supported by a Natural Sciences and Engineering Research Council of Canada Discovery Grant 2021-03431 and start-up funds provided by the Ryerson University Faculty of Science. A.M.S. was supported by a National Health and Medical Research Council (NHMRC, Australia) Investigator grant (No. 1177837).

References

1. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. *Cell* **141**, 1117–1134 (2010).
2. Wee, P. & Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers (Basel)*. **9**, (2017).
3. Yarden, Y. & Shilo, B.-Z. SnapShot: EGFR Signaling Pathway. *Cell* **131**, 1018.e1-1018.e2 (2007).
4. Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. *Cell* **61**, 203–212 (1990).
5. Lax, I. *et al.* Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. *EMBO J.* **8**, 421–427 (1989).
6. Özcan, F., Klein, P., Lemmon, M. A., Lax, I. & Schlessinger, J. On the nature of low- and high-affinity EGF receptors on living cells. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 5735–5740 (2006).
7. Boonstra, J., Mummery, C., van der Saag, P. & de Laat, S. Two receptor classes for epidermal growth factor on pheochromocytoma cells, distinguishable by temperature, lectins, and tumor promoters. *J. Cell. Physiol.* **123**, 347–352 (1985).
8. Gross, J. L., Krupp, M. N., Rifkin, D. B. & Lane, M. D. Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells. *Proc. Natl. Acad. Sci. U. S. A.* **80**, 2276–2280 (1983).
9. Saito, M., Ueno, I. & Egawa, K. Effect of retinoic acid and 12-O-tetradecanoyl phorbol-13-acetate on the binding of epidermal growth factor to its cellular receptors. *BBA - Gen. Subj.* **717**, 301–304 (1982).
10. Lund, K., Opresko, L., Starbuck, C., Walsh, B. & Wiley, H. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization - PubMed. *J Biol Chem* **265**, 15713–23 (1989).
11. Garrett, T. P. J. *et al.* Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor [alpha]. *Cell* **110**, 763–773 (2002).
12. Ogiso, H. *et al.* Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains. *Cell* **110**, 775–787 (2002).
13. Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. *Cell* **125**, 1137–1149 (2006).
14. Orellana, L. *et al.* Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 10009–10018 (2019).
15. Bessman, N. J., Bagchi, A., Ferguson, K. M. & Lemmon, M. A. Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor. *Cell Rep.* **9**, 1306–1317 (2014).
16. Ferguson, K. M. *et al.* EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. *Mol. Cell* **11**, 507–517 (2003).
17. Clarke, D. T. & Martin-Fernandez, M. L. A Brief History of Single-Particle Tracking of the Epidermal Growth Factor Receptor. *Methods Protoc.* 2019, Vol. 2, Page 12 **2**, 12 (2019).
18. Sako, Y., Minoghchi, S. & Yanagida, T. Single-molecule imaging of EGFR signalling on the surface of living cells. *Nat. Cell Biol.* **2**, 168–172 (2000).
19. Danglot, L. *et al.* Role of TI-VAMP and CD82 in EGFR cell-surface dynamics and signaling. *J. Cell Sci.* **123**, 723–35 (2010).
20. Orr, G. *et al.* Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. *Biophys. J.* **89**, 1362–1373 (2005).
21. Chung, I. *et al.* Spatial control of EGF receptor activation by reversible dimerization on living cells. *Nature* **464**, 783–787 (2010).
22. Boggara, M., Athmakuri, K., Srivastava, S., Cole, R. & Kane, R. Characterization of the diffusion of epidermal growth factor receptor clusters by single particle tracking. *Biochim. Biophys. Acta* **1828**, 419–426 (2013).

23. Lidke, D., Lidke, K., Rieger, B., Jovin, T. & Arndt-Jovin, D. Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors. *J. Cell Biol.* **170**, 619–626 (2005).
24. Sergé, A., Bertaux, N., Rigneault, H. & Marguet, D. Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes. *Nat. Methods* **5**, 687–694 (2008).
25. Teramura, Y. *et al.* Single-molecule analysis of epidermal growth factor binding on the surface of living cells. *EMBO J.* **25**, 4215 (2006).
26. Lin, C. Y., Huang, J. Y. & Lo, L.-W. Exploring in vivo cholesterol-mediated interactions between activated EGF receptors in plasma membrane with single-molecule optical tracking. *BMC Biophys.* **2016** *91* **9**, 1–11 (2016).
27. Lidke, D. S., Lidke, K. A., Rieger, B., Jovin, T. M. & Arndt-Jovin, D. J. Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors. *J. Cell Biol.* **170**, 619–26 (2005).
28. Yasui, M., Hiroshima, M., Kozuka, J., Sako, Y. & Ueda, M. Automated single-molecule imaging in living cells. *Nat. Commun.* **2018** *91* **9**, 1–11 (2018).
29. Kim, D.-H. *et al.* Single particle tracking-based reaction progress kinetic analysis reveals a series of molecular mechanisms of cetuximab-induced EGFR processes in a single living cell. *Chem. Sci.* **8**, 4823–4832 (2017).
30. Quinn, S. D. *et al.* Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs. *Biochemistry* **58**, 286–294 (2018).
31. Ibach, J. *et al.* Single Particle Tracking Reveals that EGFR Signaling Activity Is Amplified in Clathrin-Coated Pits. *PLoS One* **10**, e0143162 (2015).
32. Zanetti-Domingues, L. C. *et al.* The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers. *Nat. Commun.* **9**, 1–17 (2018).
33. Hofman, E. G. *et al.* Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization. *J. Biol. Chem.* **285**, 39481–39489 (2010).
34. Huang, Y. *et al.* Molecular basis for multimerization in the activation of the epidermal growth factor receptor. *Elife* **5**, (2016).
35. Needham, S. R. *et al.* EGFR oligomerization organizes kinase-active dimers into competent signalling platforms. *Nat. Commun.* **7**, 1–14 (2016).
36. Sorkin, A. & Goh, L. K. Endocytosis and intracellular trafficking of ErbBs. *Exp Cell Res* **315**, 683–696 (2009).
37. Mettlen, M., Chen, P.-H., Srinivasan, S., Danuser, G. & Schmid, S. L. Regulation of Clathrin-Mediated Endocytosis. *Annu. Rev. Biochem.* **87**, 871–896 (2018).
38. Delos Santos, R. C., Garay, C. & Antonescu, C. N. Charming neighborhoods on the cell surface: Plasma membrane microdomains regulate receptor tyrosine kinase signaling. *Cell. Signal.* **27**, (2015).
39. Termini, C. M. & Gillette, J. M. Tetraspanins Function as Regulators of Cellular Signaling. *Front. cell Dev. Biol.* **5**, 34 (2017).
40. Sadej, R., Grudowska, A., Turczyk, L., Kordek, R. & Romanska, H. M. CD151 in cancer progression and metastasis: A complex scenario. *Laboratory Investigation* **94**, 41–51 (2014).
41. Berdichevski, F. & Odintsova, E. ErbB receptors and tetraspanins: Casting the net wider. *Int. J. Biochem. Cell Biol.* **77**, 68–71 (2016).
42. Murayama, Y. *et al.* The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. *J. Cell. Physiol.* **216**, 135–43 (2008).
43. Park, S.-Y., Yoon, S.-J., Freire-de-Lima, L., Kim, J.-H. & Hakomori, S. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells. *Carbohydr. Res.* **344**, 1479–86 (2009).
44. Chen, S., Sun, Y., Jin, Z. & Jing, X. Functional and biochemical studies of CD9 in fibrosarcoma cell line. *Mol. Cell. Biochem.* **350**, 89–99 (2011).
45. Odintsova, E., Sugiura, T. & Berdichevski, F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. *Curr. Biol.* **10**, 1009–12 (2000).
46. Odintsova, E., Voortman, J., Gilbert, E. & Berdichevski, F. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. *J. Cell Sci.* **116**, 4557–66

- (2003).
47. Wang, X. *et al.* Suppression of epidermal growth factor receptor signaling by protein kinase C- α activation requires CD82, caveolin-1, and ganglioside. *Cancer Res.* **67**, 9986–95 (2007).
48. André, M. *et al.* Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. *Proteomics* **6**, 1437–49 (2006).
49. Orchard-Webb, D. J., Lee, T. C., Cook, G. P. & Blair, G. E. CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. *BMC Cancer* **14**, 754 (2014).
50. Alvares, S. M., Dunn, C. A., Brown, T. A., Wayner, E. E. & Carter, W. G. The role of membrane microdomains in transmembrane signaling through the epithelial glycoprotein Gp140/CDCP1. *Biochim. Biophys. Acta* **1780**, 486–96 (2008).
51. Liu, H. *et al.* CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 1379–84 (2011).
52. Park, J.-J. *et al.* KAI1 suppresses HIF-1 α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. *BMC Cancer* **12**, 81 (2012).
53. Garay, C. *et al.* Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. *Mol. Biol. Cell* **26**, (2015).
54. Rosselli-Murai, L. K. *et al.* Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. *J. Cell Sci.* **131**, jcs208926 (2018).
55. Gao, X. *et al.* PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. *Proc. Natl. Acad. Sci.* **108**, 14509–14514 (2011).
56. F, B. *et al.* High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. *J. Cell Biol.* **110**, 491–502 (1990).
57. Sugiyama, M. G., Fairm, G. D. & Antonescu, C. N. Akt-ing up just about everywhere: Compartment-specific Akt activation and function in receptor tyrosine kinase signaling. *Front. Cell Dev. Biol.* **7**, 70 (2019).
58. Delos Santos, R. *et al.* Selective control of clathrin-mediated endocytosis and clathrin-dependent signaling by phospholipase C and Ca²⁺ signals. *Mol. Biol. Cell* **28**, 2802–2818 (2017).
59. Lucarelli, S., Pandey, R., Judge, G. & Antonescu, C. N. Similar requirement for clathrin in EGF- and HGF-stimulated Akt phosphorylation. *Commun. Integr. Biol.* **9**, e1175696 (2016).
60. Lucarelli, S., Delos Santos, R. C. & Antonescu, C. N. *Measurement of epidermal growth factor receptor-derived signals within plasma membrane clathrin structures. Methods in Molecular Biology* **1652**, (2017).
61. Helmuth, J. A., Paul, G. & Sbalzarini, I. F. Beyond co-localization: inferring spatial interactions between sub-cellular structures from microscopy images. *BMC Bioinformatics* **11**, (2010).
62. Vega-Lugo, J., Rocha-Azevedo, B. da, Dasgupta, A., Touret, N. & Jaqaman, K. Analysis of conditional colocalization relationships and hierarchies in three-color microscopy images. *bioRxiv* 2021.06.16.448703 (2022). doi:10.1101/2021.06.16.448703
63. Johns, T. *et al.* Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. *J. Biol. Chem.* **279**, 30375–30384 (2004).
64. Gan, H. K., Burgess, A. W., Clayton, A. H. A. & Scott, A. M. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. *Cancer Res.* **72**, 2924–2930 (2012).
65. Garrett, T. P. J. *et al.* Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 5082–5087 (2009).
66. Aguet, F., Antonescu, C., Mettlen, M., Schmid, S. & Danuser, G. Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint. *Dev. Cell* **26**, (2013).
67. Macdonald-Obermann, J. L. & Pike, L. J. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors. *J. Biol. Chem.* **293**, 13401–13414 (2018).
68. Gustafson-Wagner, E. & Stipp, C. S. The CD9/CD81 Tetraspanin Complex and Tetraspanin CD151 Regulate $\alpha\beta$ 1 Integrin-Dependent Tumor Cell Behaviors by Overlapping but Distinct Mechanisms. *PLoS One* **8**, e61834 (2013).

69. Seipold, L. & Saftig, P. The emerging role of tetraspanins in the proteolytic processing of the amyloid precursor protein. *Front. Mol. Neurosci.* **9**, (2016).
70. Charrin, S., Jouannet, S., Boucheix, C. & Rubinstein, E. Tetraspanins at a glance. *J. Cell Sci.* **127**, 3641–8 (2014).
71. Fekri, F. *et al.* Targeted enhancement of flotillin-dependent endocytosis augments cellular uptake and impact of cytotoxic drugs. *Sci. Rep.* **9**, (2019).
72. Cabral-Dias, R. *et al.* Fyn and TOM1L1 are recruited to clathrin-coated pits and regulate Akt signaling. *J. Cell Biol.* **221**, (2022).
73. Reilly, E. B. *et al.* Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. *Mol. Cancer Ther.* **14**, 1141–1151 (2015).
74. Bone, L. N. *et al.* The acyltransferase LYCAT controls specific phosphoinositides and related membrane traffic. *Mol. Biol. Cell* **28**, (2017).
75. Aguet, F., Antonescu, C. N., Mettlen, M., Schmid, S. L. & Danuser, G. Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint. *Dev. Cell* **26**, 279–91 (2013).
76. Jaqaman, K. *et al.* Robust single-particle tracking in live-cell time-lapse sequences. *Nat. Methods* **5**, 695–702 (2008).
77. Freeman, S. A. *et al.* Transmembrane Pickets Connect Cyto- and Pericellular Skeletons Forming Barriers to Receptor Engagement. *Cell* **172**, 305-317.e10 (2018).
78. K, J. *et al.* Cytoskeletal control of CD36 diffusion promotes its receptor and signaling function. *Cell* **146**, 593–606 (2011).
79. Fekri, F. *et al.* Targeted enhancement of flotillin-dependent endocytosis augments cellular uptake and impact of cytotoxic drugs. *Sci. Rep.* **9**, (2019).
80. Boggara, M., Athmakuri, K., Srivastava, S., Cole, R. & Kane, R. S. Characterization of the diffusion of epidermal growth factor receptor clusters by single particle tracking. *Biochim. Biophys. Acta - Biomembr.* **1828**, 419–426 (2013).
81. Berg, H. C. Random Walks in Biology: New and Expanded Edition. 152 (1993).
82. Metropolis, N. & Ulam, S. The Monte Carlo Method. *J. Am. Stat. Assoc.* **44**, 335–341 (1949).

Figures

Figure 1. SPT analysis reveals that ligand binding is gated and restricted to a subset of EGFR. (A) Diagram showing labeling strategies for detection of ligand-bound receptors (via EGF-Cy3B, top panels) or all receptors, regardless of ligand binding status (via Fab-Cy3). Shown (left panels) are representative single-frames of time lapse image series obtained by TIRF-M using each labeling strategy, as used for SPT analysis. Scale 3 μ M. Also shown (right panels) are the results of the tracking showing traces of the EGFR particles over 25 frames (0.5s). Scale 10 μ M (B-C) Results of SPT analysis. (B) Shown are the mean $\pm$ SE of the fraction of all EGFR tracks, as labelled by Fab-Cy3B (left panels), or the fraction of only ligand-bound EGFR, as labeling EGF-Cy3B (right panels) that exhibit mobile, confined or immobile behaviour. (C) Shown are mean $\pm$ SE of diffusion coefficient (C) or the confinement radius (D). EGF-Cy3B (ligand-bound) data is from 5 independent experiments, and Fab-Cy3B (total EGFR) data is from 4 independent experiments. Each experiment involved detection and tracking of >500 EGFR objects. *, $p < 0.05$

Figure 2. EGF stimulation causes a redistribution of bulk EGFR from tetraspanin nanodomains to clathrin nanodomains. ARPE-19 cells stably expressing eGFP-clathrin were labeled with Fab-Cy3B (to label total EGFR) and stimulated with EGF as indicated, followed by fixation and staining with CD81 antibodies. (A) Shown are representative images obtained by TIRF-M; antibody labeling of tetraspanins is highly specific (**Fig. S2**); similar experiments with labeling of CD82 and CD151 were performed (**Fig. S4**). Scale = 5 μ m. (B-E) Shown are results of detection of EGFR objects followed by *intensity-based analysis* of EGFR object overlap with the indicated secondary channel (tetraspanins or clathrin) following subtraction of background (as described in Methods) with CD81 (B), CD82 (C), CD151 (D) or clathrin (E). $n > 3$ independent experiments each with > 10 cells and > 5000 EGFR objects quantified. Shown are the means of maker intensity within EGFR objects in individual experiment (dots), and the overall mean $\pm$ SE; *, $p < 0.05$ relative to basal condition. (F-H) Shown are results showing the overlap of EGFR and tetraspanin objects followed by *position-based analysis* of EGFR and secondary markers, as described in Methods. Shown are the individual measurements per cell, grouped by individual experiments (circle, triangle, diamond), and experimental mean for actual image pairs (blue) and EGFR relative to randomized position of the secondary channel (black). *, $p < 0.05$

Figure 3. A subset of EGFR is confined within tetraspanin nanodomains and exhibits preferential EGF binding. ARPE-19 cells were treated with siRNA to silence CD81 or non-targeting siRNA (control), as indicated. (A-I) Results of SPT analysis. The cells were then subjected to SPT using either Fab-Cy3B to label total EGFR in the absence (A, D, G) or presence (B, E, H) of unlabelled EGF, or labelled using EGF-Cy3B (C, F, I), to label only ligand-bound EGFR. Shown in A-C are the mean $\pm$ SE of the fraction of EGFR tracks in each mobility category (immobile, confined, mobile) under each condition, as well as in A-B the same data re-plotted to view the immobile and confined fractions. Also shown are mean $\pm$ SE of diffusion coefficient (D-F) or the confinement radius (G-I). EGF-Cy3B (ligand-bound) data is from 4 independent experiments, and Fab-Cy3B (total EGFR) data is from 5 independent experiments. Each experiment involved detection and tracking of >500 EGFR objects. *, $p < 0.05$

Figure 4. Tetraspanin nanodomains regulate EGFR ligand binding. (A) ARPE-19 cells were either (i) pre-labelled with Fab-Cy3B (to label total EGF), and then treated with unlabelled EGF as indicated, or (ii) labelled with EGF-Cy3B for short times (as low as 15s) as indicated. After this labeling, cells were fixed, stained for CD82, and subject to TIRF-M imaging and analysis as described in Methods. Shown are representative images (left panel), and the measurement of the fraction of Cy3B puncta within CD82 tetraspanin nanodomains in an individual experiment showing the distribution of measurements in individual cells (middle panel) and the mean of these values from $n=4$ individual experiments (right panel). *, $p < 0.05$. (B) ARPE-19 cells were transfected with siRNA targeting CD81 or 4 tetraspanins simultaneously (4x-tet: CD81, CD82, CD151 and CD9), then labelled with Cy3B-EGF for 2 min at 37°C, followed by rapid washing and fixation. Shown are representative images of cell surface Cy3B-EGF labeling (left panels), scale 20 μ m, as well as the mean intensity of cell surface EGF-Cy3B labeling per cell, normalized to cell surface EGFR levels in each condition (**Fig. S10**). Shown are the overall mean (bars) and the mean cellular values from individual experiments (dots) $\pm$ SE; *, $p < 0.05$ relative to control siRNA condition. (C) Intact (non-permeabilized) cells were incubated with mAb806 at 37°C for 5 min, followed by fixation and washing of unbound antibodies. Shown are representative images obtained by TIRF microscopy, as well as quantification of mAb806 binding, normalized to cell surface EGFR levels in each condition (**Fig. S10**). Shown are the overall mean (bars) and the mean cellular values from individual experiments (dots) $\pm$ SE; *, $p < 0.05$ relative to control siRNA condition. Scale 20 μ m.

Figure 5. Clathrin silencing preferentially impacts confinement of ligand-bound EGFR. APRE-19 cells were subject to treatment with siRNAs targeting clathrin heavy chain (clathrin) or non-targeting siRNA (control, con.). The cells were then subjected to SPT using either Fab-Cy3B to label total EGFR in the absence (A, D, G) or presence (B, E, H) of unlabelled EGF, or labelled using EGF-Cy3B (C, F, I), to label only ligand-bound EGFR). Shown in A-C are the mean $\pm$ SE of the fraction of EGFR tracks in each mobility category (immobile, confined, mobile) under each condition. Also shown are mean $\pm$ SE of diffusion coefficient (D-F) or the confinement radius (G-I). EGF-Cy3B (ligand-bound) data is from 6 independent experiments, and Fab-Cy3B (total EGFR) data is from 4 independent experiments. Each experiment involved detection and tracking of >500 EGFR objects. *, $p < 0.05$. (J) Shown is an additional analysis of the images shown in **Fig. 2** involving detection of CD81 objects followed by *intensity-based analysis* of overlap with eGFP-clathrin, following subtraction of background (as described in Methods) $n = 3$ independent experiments each with >10 cells and >5000 EGFR objects quantified. Shown are the means of eGFP clathrin intensity within CD81 objects in individual experiment (dots), and the overall mean $\pm$ SE; *, $p < 0.05$ relative to basal condition. (K) Shown is an additional analysis of the images shown in **Fig. 2**. Results of conditional, *position-based analysis* of clathrin overlap with CD81, based on the additional presence of EGFR, as described in Methods. Shown are the individual measurements per cell of clathrin colocalization with CD81 (regardless of EGFR context, left panels), clathrin colocalization with CD81 (conditional on additional co-localization of EGFR objects, middle panels, shaded grey), clathrin colocalization with CD81 (conditional on exclusion from co-localization of EGFR objects, right panels). Individual cellular values are grouped by individual experiments (circle, triangle, diamond), and experimental mean for actual image sets (blue) as well as that from randomized position of clathrin (black) and EGFR (green) channel objects relative to CD81 objects. *, $p < 0.05$, †, $p < 0.5$ relative to corresponding colocalization extent in (i) clathrin w/CD81 (irrespective of EGFR), (ii) clathrin w/ (CD81 w/EGFR) with randomized clathrin positions and (iii) clathrin w/ (CD81 w/EGFR) with randomized EGFR positions.

Figure 6. Model of EGFR compartment transitions. A) EGFR (blue) compartmentalization and ligand-binding model. Unliganded EGFR outside of nanodomains cannot become ligand-bound. EGFR can transition into a tetraspanin domain (turquoise), where EGF (orange) binding is permitted. Unliganded EGFR slowly exit a tetraspanin domain, while ligand-bound EGFR rapidly depart a tetraspanin domain and can be confined to a clathrin domain and removed from the membrane. The k_i describe the rates of transition between compartments. B) shows the confined EGFR fractions from a stochastic quantitative model of EGFR diffusion and ligand binding dynamics on the membrane, following (A). The black solid line represents the fraction of all EGFR that are confined to nanodomains, comparable to immobile + confined fraction in the left panel of Fig. 1B. The blue solid line represents the fraction of liganded EGFR confined to nanodomains, comparable to the immobile + confined fraction in the right panel of Fig. 1B. Red and magenta dashed lines represent the fraction of all EGFR confined to tetraspanin and clathrin nanodomains, respectively, comparable to the control data in Fig. 2C. This data is for slow unliganded EGFR entry and exit from tetraspanin nanodomains. Each data point is averaged over 100 EGFR trajectories.

Figure 7. Silencing specific tetraspanins regulates EGFR signaling. ARPE-19 cells were treated with siRNA to silence CD81 or CD9, CD81, CD82 and CD151 concomitantly (4x-tet), or non-targeting siRNA (control). Following silencing, cells were stimulated with 10 ng/mL EGF as indicated for 1-5 min. (A) Western blots showing various phosphorylated or total protein levels or GAPDH (loading control). (B) Mean $\pm$ SE along with measurements from $n=4$ individual experiments (dots) of phospho-EGFR (Y1068), relative to cell surface EGFR in each condition (**Fig. S10**) are shown. (C-E) ARPE-19 cells were subjected to SPT using 10 ng/mL EGF-Cy3B to label only ligand-bound EGFR in the absence (10 ng/mL EGF total) or presence of an additional 90 ng/mL unlabelled EGF (100 ng/mL EGF total). (C) The mean $\pm$ SE of the fraction of EGFR tracks in each mobility category (immobile, confined, mobile) under each condition, as well as in A-B the same data re-plotted to view the immobile and confined fractions. Also shown are mean $\pm$ SE of diffusion coefficient (D) or the confinement radius (E). Data is from $n=3$ independent experiments. Each experiment involved detection and tracking of >500 EGFR objects. *, $p < 0.05$. (F) Western blots of ARPE-19 cells treated with siRNA and stimulated as in (A-B) probed for phospho-EGFR (Y992) or other proteins as indicated (left panels). Also shown are the mean $\pm$ SE along with measurements from $n=4$ individual experiments (dots) of phospho-EGFR (Y992), relative to cell surface EGFR in each condition (**Fig. S10**); EGF. *, $p < 0.05$.

Figure 8. Tyrosine kinase inhibitors selectively alter confinement of ligand-bound EGFR. (A) ARPE-19 cells were pre-treated with 2 μ M erlotinib for 20 min, followed by stimulation with EGF as indicated for 5 min. Intact (non-permeabilized) cells were incubated with mAb806 at 37°C for 5 min, followed by fixation and washing of unbound antibodies. Shown are representative images obtained by TIRF microscopy, as well as quantification of mAb806 binding. Scale 20 μ m. (B-J) Results of SPT analysis following 20 min 2 μ M erlotinib pre-treatment, as indicated. The cells were then subjected to SPT using either Fab-Cy3B to label total EGFR in the absence (C, E, H) or presence (D, F, I) of unlabelled EGF, or labelled using EGF-Cy3B (B, G, J), to label only ligand-bound EGFR). Shown in B-D are the mean $\pm$ SE of the fraction of EGFR tracks in each mobility category (immobile, confined, mobile) under each condition, as well as in A-B the same data re-plotted to view the immobile and confined fractions. Also shown are mean $\pm$ SE of diffusion coefficient (E-G) or the confinement radius (H-J). EGF-Cy3B (ligand-bound) data and Fab-Cy3B (total EGFR) data are each from 3 independent experiments, each involving detection and tracking of >500 EGFR objects. *, $p < 0.05$